Aripiprazole versus risperidone for treatment of autism
Phase 3
- Conditions
- Pervasive developmental disorders.Childhood autism
- Registration Number
- IRCT201110233930N15
- Lead Sponsor
- Vice chancellor for research, Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Inclusion Criteria: DSM-IV diagnosis of autism spectrum disorders; both genders; being able to eat medication; providing written informed consent.
Exclusion Criteria
unstable medical condition; evidence of active liver disease; unstable hypertension or cardiac disease; unstable asthma; and kidney disease as determined by the investigator; subjects who are allergic to the medications; initiation of new behavioral therapy.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Abbrant Behavior Checklis. Timepoint: every 4 week. Method of measurement: interview.
- Secondary Outcome Measures
Name Time Method Adverse effects. Timepoint: every 4 week. Method of measurement: interview.